| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
We investigated the involvement of TRPM8 in hyperalgesia in normal and experimental colitis and irritable bowel syndrome (IBS) model animals.
TRPM8 immunoreactivity in the distal colon was much higher than in the transverse and proximal colon under physiological conditions. TRPM8 immunoreactivity markedly increased in the distal colon mucosa of colitis model mice compared with the control mice. The number of TRPM8 nerve fibers in mucosa of colitis model mice drastically increased compared with the control. Intracolonic administration of WS-12 induced behavioral visceral pain-like responses. The numbers of these responses in the colitis model were 3 times higher than in the control, and were decreased by pretreatment with the TRPM8 channel blocker AMTB. In IBS model, the number of TRPM8 nerve fibers in mucosa of butyrate-induced IBS model also increased compared with the control. Increased expression of TRPM8 may contribute to the visceral hyperalgesia of experimental colitis and IBS.
|
